Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
The conclave brought together over 1,000 delegates from across India and internationally
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
Bolli will lead worldwide business development for the company’s Contract Development and Manufacturing Organisation (CDMO) services
Focus on preventive, tech-driven healthcare and digital ecosystem reforms under AB PM-JAY and ABDM
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Subscribe To Our Newsletter & Stay Updated